NTLA

Intellia Therapeutics, Inc. (NTLA) is a pioneering gene editing company based in Cambridge, Massachusetts, specializing in the development of transformative therapies for genetic disorders using its proprietary CRISPR/Cas9 technology. The company is advancing a diverse pipeline of innovative treatment candidates currently in clinical trials, underscoring its commitment to precision medicine. As a frontrunner in the gene editing landscape, Intellia benefits from a strong intellectual property foundation and strategic collaborations that enhance its growth potential and influence within the biotechnology sector.